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ABSTRACT 
 
Metastasis is one of the most enigmatic aspects of cancer pathogenesis and is a major cause of 
cancer-associated mortality. Secondary bone cancer (SBC) is a complex disease caused by 
metastasis of tumor cells from their primary site and is characterized by intricate interplay of 
molecular interactions. Identification of targets for multifactorial diseases such as SBC, the most 
frequent complication of breast and prostate cancers, is a challenge. Towards achieving our aim of 
identification of targets specific to SBC, we constructed a ‗Cancer Genes Network‘, a 
representative protein interactome of cancer genes. Using graph theoretical methods, we obtained 
a set of key genes that are relevant for generic mechanisms of cancers and have a role in 
biological essentiality. We also compiled a curated dataset of 391 SBC genes from published 
literature which serves as a basis of ontological correlates of secondary bone cancer. Building on 
these results, we implement a strategy based on generic cancer genes, SBC genes and gene 
ontology enrichment method, to obtain a set of targets that are specific to bone metastasis. 
Through this study, we present an approach for probing one of the major complications in cancers, 
namely, metastasis. The results on genes that play generic roles in cancer phenotype, obtained by 
network analysis of ‗Cancer Genes Network‘, have broader implications in understanding the role 
of molecular regulators in mechanisms of cancers. Specifically, our study provides a set of 
potential targets that are of ontological and regulatory relevance to secondary bone cancer. 
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INTRODUCTION 
 
Cancer is a disease of multiple systems and components that interact at both molecular and 
cellular levels leading to initiation, progression and spread of the disease [1,2]. The changing 
interactions of these systems in a dynamic environment underscore the inherent complexity of the 
disease. Until recently, cancer has been studied with a reductionist approach focusing on a specific 
mutation or a pathway. Lately there has been a tremendous increase in systems-level study of 
cancer and the use of integrative approaches to understand mechanisms of cancers [3,4] and their 
metastases [5,6]. 
 
Metastasis is one of the most enigmatic hallmarks of cancers characterized by complex molecular 
interactions [1,7]. It is responsible for as much as 90% of cancer-associated mortality, yet remains 
the most poorly understood component of cancer pathogenesis [7,8]. Tumor metastasis is a 
multistage process during which malignant cells spread from the primary tumor to discontiguous 
organs [7]. Metastatic dissemination involves a sequence of steps involving invasion, intravasation, 
extravasation, survival, evasion of host defense and adaptation to the foreign microenvironment 
[7,8].  
 
Secondary bone cancer (SBC) is a complex disease involving interplay of osteolytic and 
osetoblastic mechanisms [9] (Figure 1). Bone metastases are the most frequent complication of 
breast and prostate cancers with a very high propensity of metastasizing to bone causing bone 
pain, fracture, hypercalcemia and paralysis [10–13]. Breast and prostate carcinomas are often 
known to take years to develop metastatic colonies (in a limited number of sites) suggesting that in 
these cancers, cells employ distinct adaptive programs to laboriously cobble together complex 
shifts in gene-expression programs [14]. Many molecules and associated pathways are reported to 
be involved in metastasis of cancer cells from breast cancer [13,15–22] and those from prostate 
cancer [10,18,23–30].  
 
Cancers are characterized by hallmark processes and shared mechanisms involved in expression 
of disease phenotype. It is a challenge to identify such genes involved in generic cancer 
mechanisms. Identification of such ‗generic cancer genes‘ may help us focus on ‗disease specific 
cancer genes‘ of potential therapeutic value. Due to complexity and subtle mechanisms involved in 
metastasis, it is difficult to identify their control mechanisms. Therefore it is important to have 
methods for identification of genes and regulatory mechanisms that are key to a complex 
pathogenic state such as secondary bone cancer. Complex network models of interactomes, along 
with graph-theoretical analysis and overrepresentation studies, present us a useful strategy for 
probing molecules that are central to SBC mechanisms and hence potential therapeutic targets.  
 
Cellular functions reflect the state of the cell as a function of an intricate web of interactions among 
large number of genes, metabolites, proteins and RNA molecules. A disease phenotype reflects 
various pathobiological processes that interact in a complex network and is rarely a consequence 
of abnormality in a single effector gene product [3]. Understanding diseases in the context of 
organizing principles of the architecture of biological networks allows us to address some 
fundamental properties of genes that are involved in disease. Study of disease protein 
interactomes offer a better understanding of disease-specific genes and processes involved and 
may offer better targets for drug development. Molecular interaction networks are characterized by 
the presence of a few highly connected nodes, often called hubs, suggesting a special role of 
these promiscuous interactors. Hubs of protein interactomes are more likely to be essential for the 
survival [31] and also reported to be important for cellular growth rate [32]. Proteins with high 
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betweenness [33,34] are reported to have much higher tendency to be essential genes [35,36]. 
Cancer proteins are reported to be more central in the protein interactome and are, on an average, 
involved in twice as many interactions as those of non-cancer proteins [37]. 
 
The Gene Ontology [38] project provides an ontology of defined terms representing gene product 
properties. The ontology covers three domains: cellular component, parts of a cell or its 
extracellular environment; molecular function, elemental activities of a gene product at the 
molecular level and biological process, sets of molecular events with a defined beginning and end, 
pertinent to the functioning of integrated living units. GO enrichment methods provide a way to 
extract biological insight from a set of genes using the power of gene sets [39]. Enrichment 
analysis involves identification of GO terms that are significantly overrepresented in a given set of 
genes using statistical models such as hypergeometric and chi squared distributions [40]. A large 
repertoire of tools has been developed in recent years for enrichment analysis [41,42]. Methods of 
network analysis and enrichment studies have been effectively used to identify targets of diseases 
such as chronic fatigue syndrome [43], major depressive disorder [44], glioblastoma [45], 
colorectal carcinogenesis [46] and primary immunodeficiency disease [47]. 
 
In this study, we aimed to identify secondary bone cancer specific genes. Towards this goal, we 
used a composite strategy (Figure 2) involving identification of cancer genes specifying generic 
cancer mechanisms, compilation of genes implicated in metastasis to bone and identification of 
genes annotated with GO terms specific to secondary bone cancer, to obtain disease specific 
targets. While network analysis provides a systems perspective of complex molecular mechanisms 
and helps to identify its central components (functional elements), gene enrichment method 
enables identification of characteristic ontological features of the gene sets. We first constructed a 
representative protein interactome of all cancer genes and obtained hubs that are involved in 
generic cancer mechanisms. Further, we compiled a set of experimentally verified genes from the  
literature that is involved in metastasis of primary breast and prostate cancer into bone, the 
dominant cause of secondary bone cancer.  Using a combination of protein interactome analysis 
and gene ontology enrichment studies, we obtained a set of genes (targets) specific to SBC 
mechanisms. Our study provides an approach to identify targets specific to a complex disease 
phenotype (bone metastasis) by combining systems-level interactome analysis and ontological 
studies. 
 
RESULTS 
 
CGN as a representative interactome of cancer mechanisms  
 
We intended to construct an interactome that represents mechanisms involved in processes 
contributing to cancers. For this purpose we used genes listed in CancerGenes database [48], a 
compilation of cancer genes that are causally implicated in oncogenesis. We obtained 3164 cancer 
genes from CancerGenes database, which were used to construct an interactome. These genes 
were mapped on Human Protein Reference Database [49], a database of curated proteomic 
information pertaining to human proteins, to construct the Cancer Genes Network (CGN).  CGN 
thus represents an intricate network of cancer proteins. CGN comprises 11602 interactions among 
2665 proteins. Figure 3 depicts the CGN, a representative protein interactome of molecular agents 
and their regulatory interactions, involved in disease phenotype of cancers. Based on earlier 
reports [3], we hypothesize that proteins that are key to the structural integrity and interaction 
dynamics of CGN would correspond to proteins involved in regulatory mechanisms generic to 
cancers.  
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Topologically central genes of CGN correlate to generic cancer mechanisms  
 
Molecular interaction networks have been reported to have a scale-free nature marked by the 
presence of few hubs that are critical for the networks [50]. Such hubs of protein interactomes are 
reported to be more essential for the survival [31] and also important for cellular growth rate [32]. 
Proteins with high betweenness are reported to have much higher tendency to be essential genes 
[35,36]. Cancer proteins are reported to be more central in the protein interactome and are, on an 
average, involved in twice as many interactions as non-cancer proteins [37]. As reported for other 
biological molecular networks [50,51], we find that CGN has a scale-free nature indicating 
presence of exceptionally promiscuously interacting hub nodes and those mediating a large 
number of interactions (Figure 4) [52].   
We computed seven parameters that reflect topological features (degree [53] and neighborhood 
connectivity [54]), network flow (betweenness [33,34], stress [33,34] and average shortest path 
length [55]) and local clustering (clustering coefficient [53,55,56] and topological coefficient [57]). 
The ‗key‘ proteins, that are topologically and dynamically central to CGN, were identified by 
network analysis. For this purpose ‗degree‘, ‗stress‘ and the normalized counterpart of the latter, 
‗betweenness‘, were used for identification of central proteins of CGN. We find that the selected 
parameters show very high mutual positive correlations (Figure 5). The best-ranked proteins from 
each of these parameters were compiled, for various thresholds (Top25—Top200), to identify 
proteins designated as ‗hubs‘ (Set-A in Figure 2 and Supplementary Information Table S1.1). 
We find that the ‗hubs‘ (Figure 3; Top75 threshold), thus identified, include genes involved in 
regulation of processes known to be generically present in most cancers [1]. Proteins known to be 
involved in growth signals, thus leading to self-sufficiency in cancer cells, such as TGFBR1, EGFR, 
IGFR1R, GRB2, are in the ‗hubs‘ of CGN [2]. The hubs also include RB1, BCL2, AKT1, CDK2, 
CASP8 which are involved in mechanisms of apoptosis, to which cells are known to acquire 
resistance in all types of cancers [1,58]. The TP53 tumor suppressor protein, known to be involved 
in most commonly occurring loss of proapoptotic regulation and affecting the apoptotic effector 
cascade [59,60], is also present in the CGN hubs. One of the hub proteins, SMAD4, is known to be 
involved in differentiation, apoptosis and cell cycle [61]. MYC, known to upregulate cyclins and 
downregulate CDKN1A (P21), is also one of the hubs of CGN. 
Further, we checked how well the identified hubs correlate with KEGG-PIC [62], a collection of 
genes from generic pathways involved in cancers (Supplementary Information Table S1.2).  Figure 
6 shows the overlap of hub genes (Top25 to Top200) with KEGG-PIC genes. We find that indeed 
the Top25 hubs, comprising the most promiscuously interacting proteins and mediating a large 
number of interactions in cancer genes interactome, have a 74% overlap with KEGG-PIC. The 
precision of identification of generic cancer proteins drops as the definition of ‗hubs‘ is relaxed 
further (57% for Top50 and 52% for Top75). As a negative control, for the ability of network-metrics-
based ranking to identify generic proteins, we use genes ranked worst according to the selected 
parameters. We find that these genes have a very poor overlap with KEGG-PIC genes, even when 
compared to that expected from corresponding random samplings (Figure 6). We treat Top25, 
Top50 and Top75 CGN hubs as representatives of generic cancer genes and use them, further, to 
identify SBC-specific targets. 
GO enrichment of CGN hub genes  
 
5 
 
We performed GO enrichment analysis of CGN ‗hub‘ genes identified. We expect the ‗hubs‘ to 
represent generic cancer processes which are shared by most, and perhaps, all types of human 
cancers. The molecular machinery regulating proliferation, differentiation and death of all 
mammalian cells is highly similar [1]. The genetic transformation of normal body cells results in 
defects of regulatory circuits that govern normal cell proliferation and homeostasis, and collectively 
dictate malignant growth.  
Cancer cells show self-sufficiency of growth signals involving alteration of transcellular or 
intracellular mechanisms [2]. The growth signaling pathways are suspected to suffer deregulation 
in all human tumors [2]. This was reflected in the following significantly overrepresented GO terms 
of CGN hubs: cellular response to growth hormone stimulus (GO:0071378), regulation of 
epidermal growth factor receptor signaling pathway (GO:0042058), transforming growth factor beta 
receptor signaling pathway (GO:0007179), signal complex assembly (GO:0007172).  
In contrast to normal cells, which respond to antigrowth signals, cancerous cells are insensitive to 
antigrowth signals due to disruption of pathways related to cell cycle clock. We find that our list of 
significantly enriched GO terms for CGN hubs had many terms associated with cell cycle 
processes: mitotic cell cycle G1/S transition checkpoint (GO:0031575), regulation of G1/S 
transition of mitotic cell cycle (GO:2000045), DNA damage response, signal transduction by p53 
class mediator (GO:0030330), regulation of stress-activated MAPK cascade (GO:0007173).  
In human carcinogenesis, all types of cancers are known to acquire resistance to apoptosis [58]. 
The overrepresented GO terms of CGN hubs underline this observation: release of cytochrome c 
from mitochondria (GO:0001836), activation of pro-apoptotic gene products (GO:0008633), cell-
type specific apoptotic process (GO:0097285), cellular component disassembly involved in 
apoptotic process (GO:0006921), positive regulation of anti-apoptosis (GO:0045768).  
In addition, we find following significantly enriched ‗molecular function‘ terms: transforming growth 
factor beta receptor, pathway-specific cytoplasmic mediator activity (GO:0030618), receptor 
signaling protein tyrosine kinase activity (GO:0004716), ephrin receptor binding (GO:0046875), 
MAP kinase activity (GO:0004707), beta-catenin binding (GO:0008013), cytokine receptor binding 
(GO:0005126), androgen receptor binding (GO:0050681). 
All the GO-terms mentioned above broadly support generic cancer processes. The p-values for 
these ‗significantly enriched GO terms of CGN Top75 hubs‘ are in the range of 10e-4 and 10e-13. 
Figure 7 depicts these overrepresented GO terms and statistics of their prevalence. 
Topologically central genes of CGN correlate with biological essentiality  
 
We further checked the biological relevance of the central genes of CGN. We divided CGN into two 
sets, essential and non-essential, using Mammalian Phenotype Ontologies [63] to classify genes 
as essential when they caused embryonic, perinatal, postnatal or neonatal lethality in mouse 
models [64] using phenotypic data from Mouse Genome Informatics (MGI) [65]. The percentage of 
essential genes were computed in the ‗hubs‘ and their corresponding non-hubs for varying hub 
definitions. Figure 8 shows the statistics for percentage of hub and non-hub genes annotated as 
essential. Among the seven parameters computed, the hubs identified using degree, betweenness 
and stress have a significant percentage of essential genes (between 82% to 92%) (Figure 8A). 
Incidentally, none of the remaining four network parameters show good correlation with biological 
essentiality. The non-hubs, as expected from the random samplings statistics, have around 50% of 
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essential genes associated, regardless of the metric used for ranking (Figure 8B). For hubs 
comprising of Top75 genes, the chosen parameters have a very high proportion of essential genes 
(between 88% and 89%), compared to the rest of the parameters. Figure 3 depicts the central 
nature of Top75 hub genes of CGN and highlights the essential and non-essential genes among 
them. This emphasizes the relevance of the network metrics chosen in encoding biological 
relevance. This is consistent with earlier reports about hubs being more essential [64] and network 
centrality of cancer genes [37]. 
 
SBCGs and their characteristic GO terms  
 
Knowing that metastasis into bone is primarily caused by spread from primary prostate and breast 
cancers [10–13], we aimed at compiling genes linked with these processes. We compiled a list of 
391 Secondary Bone Cancer (SBC) susceptible genes from literature reporting experimental 
studies (Set-B in Figure 2 and Supplementary Information Table S1.3). For identifying the 
relevance of these genes in the context of metastasis into bone, we performed an 
overrepresentation analysis using CGN as universe. Gene ontology enrichment studies of SBCGs 
are expected to reflect GO categories of biological processes and molecular functions that are 
relevant for metastasis into bone, consistent with the known aspects of regulatory mechanisms of 
bone metastasis (Figure 1).  
 
We identified 93 significantly enriched GO terms of SBCGs for biological processes, molecular 
functions and cellular components. We identify CGN genes annotated with either of these 93 GO 
terms to construct ‗Enriched Genes‘ set (Set-C in Figure 2). We find that out of the 93 significantly 
enriched GO terms, 31 are associated with metastasis or bone processes. Out of these 31 GO 
terms, 21 are most relevant for metastasis mechanisms and 10 for bone-related processes (Figure 
9).  
 
The following GO terms, that were significantly enriched, are related to bone processes: osteoblast 
differentiation (GO:0001649), regulation of bone remodeling (GO:0046850), endochondral 
ossification (GO:0001958), replacement ossification (GO:0036075), bone mineralization 
(GO:0030282), ossification (GO:0001503), cartilage development (GO:0051216), response to 
vitamin D (GO:0033280), collagen metabolic process (GO:0032963), collagen fibril organization 
(GO:0030199).  
 
The following biological processes GO terms, that were significantly enriched, are related to 
mechanisms of metastasis: leukocyte migration (GO:0050900), cell-cell adhesion (GO:0016337), 
angiogenesis (GO:0001525), positive regulation of cell adhesion (GO:0045785), negative 
regulation of cell adhesion (GO:0007162), positive regulation of leukocyte migration 
(GO:0002687), regulation of leukocyte chemotaxis (GO:0002688), positive regulation of leukocyte 
chemotaxis (GO:0002690), positive regulation of catenin import into nucleus (GO:0035413).  
 
Following molecular functions GO terms that were significantly enriched, are related to 
mechanisms of metastasis: laminin binding (GO:0043236), fibronectin binding (GO:0001968), 
fibroblast growth factor receptor binding (GO:0005104), platelet-derived growth factor binding 
(GO:0048407), extracellular matrix binding (GO:0050840), collagen binding (GO:0005518), integrin 
binding (GO:0005178), glycosaminoglycan binding (GO:0005539), cytokine activity (GO:0005125), 
carbohydrate binding (GO:0030246). 
 
Predicted SBC-specific targets  
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For predicting SBC-specific targets of potential therapeutic value, we logically juxtaposed the three 
sets of genes obtained: CGN hub genes (Top75), SBCGs and the cancer genes annotated with 
GO terms overrepresented for SBCGs (Figure 2 and Figure 10). On the basis of specificity for 
secondary bone cancer, as depicted in Figure 10A, the Venn diagram corresponding to these gene 
sets was divided into seven distinct regions: Set-a, Set-b, Set-c, Set-ab, Set-bc, Set-ac and Set-
abc. Overall, the sets belonging to central genes of CGN (Set-a, Set-ab, Set-ac and Set-abc) 
contain genes that are involved in generic cancer mechanisms (Figure 6) and are also essential 
(Figure 8). Hence, while obtaining SBC-specific targets, we don‘t consider these gene sets. Out of 
the rest of three sets, Set-b comprises genes that are already reported to be associated with SBC 
mechanisms, hence may not reveal novel genes. We focus on Set-c and Set-bc, corresponding to 
non-generic cancer genes annotated with SBC-specific GO terms and those reported to be having 
a role in SBC mechanisms, respectively, for the search of novel SBC-specific targets. 
Set-bc and Set-c contain 53 and 134 genes, respectively. These lists were refined to select only 
those genes that are annotated with GO terms most relevant for SBC (Figure 9 and Supplementary 
Information Table S1.4), to obtain 28 and 60 genes from Set-bc and Set-c, respectively. We find 
that, in these sets, we were still left with KEGG-PIC genes known to be involved in generic cancer 
pathways. The list of targets was refined further to obtain a total of 72 targets that are non-generic 
to cancers and relevant for secondary bone cancer. 
Out of these 72 genes, 14 genes are annotated with GO terms relevant to bone processes, 51 with 
metastasis and 7 with both (Figure 3). We predict these seven proteins, with ontological relevance 
to bone processes as well as metastasis, to be most potent targets and key regulators of 
metastasis into bone. The non-generic SBC-specific targets, with relevance to metastasis and 
bone mechanisms, identified are: SPP1 (Secreted Phospoprotein 1), CD44 (Cluster of 
Differentiation 44), CTGF (Connective Tissue Growth Factor), TNXB (Tenascin X), BMP1 (Bone 
Morphogenetic Protein 1), BMPR1A (Bone Morphogenetic Protein Receptor, Type IA) and VWF 
(Von Willebrand Factor). 
We find that the SBC-specific targets identified are indeed relevant for the metastasis into bone 
and involved in regulation of SBC mechanisms (Supplementary Information Table S1.5). SPP1 is 
reported to interact with CD44 receptor and is thought to exert pro-metastatic effects leading to 
tumor progression by regulating the cell signaling events [66,67]. CD44 is also reported to enhance 
integrin-mediated adhesion and transendothelial migration of breast cancer cells [68]. CTGF 
expression has been shown to be associated with tumor development and progession. The 
overexpression of CTGF in breast cancer cells may promote their metastasis to bone [69]. 
BMPR1A, belonging to the family of transmembrane serine/threonine kinases, is reported to be 
necessary for extracellular matrix deposition by osteoblasts, while not essential for osteoblast 
formation or proliferation [70]. BMP1, which does not belong to TGF superfamily unlike other 
BMPs, is known to induce bone and cartilage development. TNXB is an extracellular matrix 
glycoprotein expressed in connective tissues including skin, joints and muscles and in known to 
have role in cell-matrix and cell-cell adhesion. It has been reported that TNX deficiency leads to the 
invasion and metastasis of tumor cells by facilitating increase in the activity of MMPs which results 
in the degradation of laminin. The over-expression of TNX could be of potential therapeutic benefit 
in reducing tumor progression [71]. VWF is a large multimeric glycoprotein present in blood plasma 
and is produced constitutively in endothelium, megakaryocytes and subendothelial connective 
tissue. It has been reported that  in osteosarcoma tumors the expression of VWF gets deregulated, 
potentially leading to metastasis [72]. 
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DISCUSSION 
Towards our goal of identifying key targets specific for mechanisms of metastases of primary 
breast and prostate cancers to bone, we used network analysis and gene ontology enrichment 
studies. The motivation behind using a combination of network analysis and gene enrichment 
methods is that, while the prior provides a systems perspective of complex molecular mechanisms 
and helps to identify its central components (functional elements), the latter enables identification 
of characteristic ontological features of the gene sets. Secondary Bone Cancer (SBC) is a complex 
disease triggered from the primary form of cancers, most commonly through breast cancer and 
prostate cancer. Many pathways and molecular regulators involved in the metastasis of primary 
prostate cancer and breast cancer are well known. Starting from SBC-related proteins and 
interactome of proteins involved in cancer mechanisms, using network analysis and 
overrepresentation studies, we identify targets that are specific to SBC. 
 
The final list of seven targets was identified using generic cancer genes obtained with Top75 hubs. 
We repeated this task with Top25 and Top50 lists, which have better overlap with KEGG-PIC genes 
(74% and 57%, respectively), as compared to that of Top75 hubs (52%) (Figure 7). Using the 
procedure described, we identified SBC-specific targets starting from Top25 and Top50 CGN hubs. 
Figure 11 illustrates the results of these experiments obtained with better overlap with generic 
cancer genes (KEGG-PIC). Using these thresholds we obtained 31 and 60 hubs, respectively, 
which were filtered from the potential target set. This resulted in increase in number of potential 
targets in Set-c to 141 and 139, respectively, compared to those obtained with Top75 hubs (134). 
There was no change in the number of genes (53) obtained in Set-bc. Even with these criteria that 
correspond better with generic genes, the number of targets (that are annotated with GO terms 
relevant to metastasis and that of bone processes) does not increase, indicating the soundness of 
criteria used for identification of SBC-specific targets.  
 
Network analysis has been shown to be a very useful and potent tool in understanding the disease 
phenotype and probing for therapeutic targets [3]. The identification of network parameters relevant 
to the question(s) being asked is an important task. We chose degree, betweenness and stress 
that are known to be important in the topology of the disease interactome and dynamic interplay of 
proteins involved [3]. These parameters were also found to have very good correlation with 
‗essential genes‘ (Figure 8). The significant terms emerging from overrepresentation analysis of 
CGN too support our choice of parameters (Figure 7). 
 
Gene Ontology (GO) defines a set of functional terms related by parenthood relationships forming 
a directed acyclic graph. It produces sets of explicitly defined, structured vocabularies that describe 
biological processes, molecular functions and cellular components of gene products [38]. GO 
classification is expected to become an increasingly powerful tool for data analysis and functional 
predictions as the ontologies and annotations continue to evolve [40]. It is characterized by high 
quality manual curation, consistent annotation standards across species, and has the advantage of 
lesser bias as compared to domain specific classification schemes due to its comprehensive 
nature [40]. GO enrichment methods, which provide means of identification of significantly 
overrepresented GO terms, could be effectively used to get biological insights from a given set of 
genes [40]. One of the critical points in GO enrichment analysis is the selection of background set 
for getting the correct results. In this study, we use a pool of cancer genes (CGN) as universe, 
which serves the purpose of a meaningful background set of cancer mechanisms.  
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Cancer is a complex genetic disease characterized by intricate regulations among a diverse set of 
cancer genes. Hence, it is useful to have a detailed map of interactions that could help in probing 
hallmark regulatory modules and perhaps cancer-specific motifs. Here, we used CancerGenes 
Database (CGDb) [48] as a premise of cancer genes to construct a representative cancer 
interactome. This could potentially be improved by compiling a more exhaustive list of cancer 
genes. Though, we believe that the ultimate set of generic cancer genes, central to the topology of 
the cancer genes network, would not alter much, it may enrich the data and enable a more 
meaningful analysis of subtle regulatory features of cancer phenotype. It would be interesting to 
see whether and how the modules of CGN reflect the hallmarks of cancers.  Also, while a few of 
the network centrality metrics for cancer genes may enumerate biological essentiality, it would be 
interesting to explore a larger parameter space to search for topological correlates of essentiality. 
We use KEGG-PIC genes as a prototype of generic cancer mechanisms. There is scope for 
improvement of this data by inclusion of generic genes through curation from landmark studies 
[1,2,73,74]. We believe that better metrics that embody structure and information dynamics over 
the cancer genes interactome could be developed that are more successful in elucidating the 
regulatory features characterizing molecular circuitries of cancers. 
 
In view of the complex and subtly intertwined regulatory mechanisms of cancers, we modeled it as 
a network of protein interactions and aimed to identify generic cancer genes that specify hallmark 
features of cancers. We find that, indeed hubs of the cancer genes interactome that are central to 
the structural integrity and dynamical interplay of proteins, correlate with genes from generic 
pathways of cancers. We believe that the methodology presented here could be useful in obtaining 
cancer-specific targets of potential therapeutic value. 
 
MATERIALS AND METHODS 
 
Cancer Genes Network (CGN) 
 
We used HPRD (Human Protein Reference Database) [49], one of the most comprehensive 
resources of human protein-protein interactions (PPIs), to construct a reference human protein 
interactome. HPRD is a manually curated human protein-protein interaction resource containing 
36617 unique human PPIs and 9427 associated proteins (Release 9: April 13, 2010).  It is one of 
the best resources of human PPIs, containing the largest number of binary non-redundant human 
PPIs, largest number of genes annotated with at least one interactor, and largest citations of PPIs 
curated [75]. 
 
The data of cancer genes involved in carcinogenesis were compiled from CancerGenes database 
[48] (as on May 2012). CancerGenes database is a compilation of cancer gene lists annotated by 
experts with information from key publicly available databases. Cancer associated genes are 
collected from various sources such as Cancer Map Pathways, Sanger Cancer Gene Census, 
Sanger Catalogue of Somatic Mutations in Cancer, reviews on cancer, Entrez queries and prostate 
cancer list. This data of 3164 cancer genes was used to compile a protein interactome 
representing molecular mechanisms of cancers. The interactions associated with proteins 
corresponding to these genes were collected from HPRD [49]. This network was called CGN 
(Cancer Genes Network), in which nodes represent cancer genes and edges represent 
experimentally validated interactions between a pair of genes i and j. Thus CGN is an intricate 
network of cancer proteins, comprising of 11602 interactions among 2665 proteins. It contains a 
giant cluster of 2376 proteins interlinked via 11590 interactions and the rest fragmented into minor 
clusters and isolated nodes (Figure 3). To adjudge the scale-free nature of degree and 
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betweenness distributions of CGN, we tested the power-law hypothesis and estimated the 
parameters for these distributions with the technique based on maximum likelihood methods and 
the Kolmogorov-Smirnov statistic (Figure 4) [52]. 
 
Secondary Bone Cancer Genes (SBCGs) 
 
We curated and compiled 391 genes involved in ‗metastasis to bone from primary prostate and 
breast cancer‘ (167 and 230 genes, respectively), through literature mining (Set-B in Figure 2). 
These genes were called SBCGs (Secondary Bone Cancer Genes). We used following keywords 
to search for SBCGs: ―secondary bone cancer genes from primary prostate cancer‖, ―secondary 
bone cancer genes from primary breast cancer‖ (Pubmed) and ―genes involved in metastasis of 
prostate cancer to bone‖, ―genes involved in metastasis of breast cancer to bone‖ (Google 
Scholar). Supplementary Information Table S1.3 provides the details of SBCGs compiled from the 
literature. 
 
Gene Ontology analysis 
 
Gene Ontology (GO) enrichment or overrepresentation analysis allows one to identify 
characteristic biological attributes in a given gene set. It is based on the hypothesis that 
functionally related genes should accumulate in the corresponding GO category. We used GOrilla 
[41], a tool to identify enriched GO terms, to obtain biological attributes characterizing CGN hub 
genes as well as SBCGs. It uses the hypergeometric distribution to identify enriched GO terms in a 
given set of genes. We performed GO enrichment using ‗two unranked lists of genes‘ mode, with 
an ‗unranked target set‘ in the background of an ‗unranked source set‘. We identify ‗significantly 
enriched GO terms‘, for Biological Process, Molecular Function and Cellular Components, with p-
value cut-off of 0.001 and those having at most 100 genes associated with, in the source data 
(B≤100). The latter criterion is used to weed out terms those are too generic. The CGN Top75 hub 
genes (target) were enriched against all genes present in CGN (source). Similarly, the SBCGs 
(target) were enriched against CGN (source). These GO enrichment experiments help us obtain 
biological attributes that characterize the CGN hubs and those characterizing SBCGs, respectively, 
in the background of ‗cancer genes‘ universe. 
 
We performed the GO enrichment studies at three different p-values (0.01, 0.001 and 0.0001) for, 
both, SBCGs and CGN Top75 gene-set. We found that the significantly enriched GO terms 
obtained for BP, MF and CC were similar for p-values 0.01 and 0.001. For stricter p-value of 
0.0001, we found that many of the GO terms relevant for secondary bone cancer and with generic 
role in cancer mechanisms, respectively, were lost. In the case of SBCGs, 14 BP and 4 MF 
disease-specific GO terms were lost at p-value 0.0001, including following key GO terms: 
angiogenesis (GO:0001525), regulation of bone remodelling (GO:0046850), bone mineralization 
(GO:0030282), collagen fibril organisation (GO:0030199), integrin binding (GO:0005178), laminin 
binding (GO:0043236), platelet derived growth factor binding (GO:0048407) and regulation of 
chemotaxis (GO:0050920). In the case of CGN Top75 gene-set analysis, 20 BP and 2 MF GO 
terms were lost, including following GO terms important for generic cancer mechanisms, at p-value 
0.0001: cellular component disassembly involved in apoptotic process (GO:0006921), positive 
regulation of MAPK cascade (GO:0043410), positive regulation of cell cycle process 
(GO:0090068), regulation of G1/S transition of mitotic cell cycle (GO:2000045), mitotic cell cycle 
G1/S transition checkpoint (GO:0031575), growth hormone receptor signaling pathway 
(GO:0060396), response to fibroblast growth factor stimulus (GO:0071774) and transforming 
growth factor beta receptor signaling pathway (GO:0007179). 
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The value of ‗B‘ (number of genes from the source set associated with a given GO term) was 
chosen to increase the ‗signal‘ (specific GO terms) and to reduce ‗noise‘ (non-specific GO terms). 
High values of ‗B‘ increase noise by populating the enrichment results with non-specific GO terms; 
whereas small values of B reduce the signal by rejecting specific and relevant GO terms. We 
performed multiple experiments at different thresholds of B-values. (i) For B≤50, we missed 6 BP 
and 3 MF GO terms specific to SBC including the following: positive regulation of cell adhesion, 
angiogenesis (GO:0001525), cell-cell adhesion (GO:0016337), cytokine activity (GO:0005125), 
glycosaminoglycan binding (GO:0005539) and carbohydrate binding (GO:0030246). Similarly, in 
the case of ACGN Top75 gene-set, 12 BP and 3 MF relevant GO terms were lost including DNA 
damage response, signal transduction by p53 class mediator (GO:0030330), regulation of DNA 
replication (GO:0006275), positive regulation of cell cycle process (GO:0090068), positive 
regulation of MAPK cascade (GO:0043410), Ras protein signal transduction (GO:0007265) and 
response to UV (GO:0009411). (ii) For 50<B≤100, we got most of the relevant terms for both 
SBCGs and ACGN Top75 gene-set. (iii) For B>100, almost all the terms obtained were non-specific 
(noise). Hence, we chose B≤100 to maximize the relevant GO terms and to reduce the non-
specific GO terms in the enrichment results. 
 
Protein interactome analysis  
 
We performed network analysis of CGN to compute various graph-theoretical metrics, using 
NetworkAnalyzer plugin of Cytoscape [76]. We computed seven network centrality parameters 
based on network connectivity (degree [53] and neighborhood connectivity [54]), network flow 
(betweenness [33,34], stress [33,34], average shortest path length [55]) and local clustering 
(clustering coefficient [53,55,56] and topological coefficient [57]). 
Degree [53] corresponds to the number of nodes adjacent to a given node v, where adjacent 
means directly connected. The degree distribution P(k) of a network is then defined to be the 
fraction of nodes in the network with degree k. Thus if there are N nodes in total in a network and 
nk of them have degree k, we have P(k) = nk/N.  
‗Neighbourhood connectivity‘ [54] of a node 𝑣 is defined as the average connectivity of all 
neighbors of 𝑣. For a node 𝑣 with 𝑘𝑣 number of neighbors, the neighborhood connectivity is 
defined as: 
𝑛𝑐 𝑣 ≡  
 𝑘𝑤𝑤∈𝑊
𝑘𝑣
 
Where W is the set of neighbors of 𝑣, and 𝑘𝑤  is the degree of each of the neighboring node. 
 
‗Stress‘ [33,34] and (its normalized counterpart) ‗betweenness‘ [33,34] enumerate number of 
shortest paths from all pairs of vertices passing through the node of interest. In a graph G = (V, E) 
with N nodes, stress (𝑠𝑡𝑟(𝑣)) is defined as the total number of shortest paths passing through a 
node 𝑣: 
𝑠𝑡𝑟(𝑣) ≡   𝜎𝑠𝑡  𝑣 
𝑡≠𝑣∈𝑁𝑠≠𝑣∈𝑁
 
Where, 𝜎𝑠𝑡  𝑣  is the number of shortest paths from s to t that pass through vertex 𝑣. Betweenness 
is normalized (with the total number of shortest paths in graph G,  𝜎𝑠𝑡𝑠≠𝑣≠𝑡∈𝑉
𝑠≠𝑡
) value of stress. 
The higher the value of stress/betweenness, the higher is the relevance of the protein as a critical 
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mediator of regulatory molecules and/or functional modules.  
 
The average shortest path length [55] of a vertex 𝑣 in graph G, corresponds to the average of all 
the shortest paths between 𝑣 and the rest of the vertices. The average shortest path length of 
vertex 𝑣 is defined as: 
𝑎𝑠𝑝 𝑣 ≡  
𝑑𝑖𝑠𝑡 𝑣, 𝑤 
 𝑁 − 1 
 𝑤≠𝑣𝜖𝑉
 
Where V is the set of nodes in G, dist(𝑣,w) is the shortest path from 𝑣 to 𝑤, and N is the number of 
nodes in G. 
 
Clustering Coefficient 𝐶𝑣 [53,55,56] of a node 𝑣 is defined as: 
𝐶𝑣 ≡  
2𝑒𝑣
𝑘𝑣 (𝑘𝑣 − 1)
 
 
Where 𝑘𝑣  is the number of neighbors of 𝑣 and 𝑒𝑣 is the number of connected pairs of nodes 
between all neighbors of 𝑣. 
 
Topological Coefficient 𝑡𝑐(𝑣) [57] of a node 𝑣 is defined as, 
𝑡𝑐 𝑣 ≡
 𝐽 𝑣, 𝑤  𝑤≠𝑣𝜖𝑉
𝑘𝑣
 
 
Where V is the set of nodes in G and J(𝑣,w) is the number of neighbors shared between the nodes 
𝑣 to 𝑤, plus one if there is a direct link between 𝑣 and 𝑤. 
 
We used degree, betweenness and stress metrics for identification of hubs of CGN. These metrics 
have been reported to be useful in identification of hubs of biological relevance [31,35,36] and 
those relevant to cancer [37]. 
 
Identification of hub nodes and their controls  
 
First, we ranked the genes of CGN for each of the chosen parameters (degree, betweenness and 
stress). Then, we compiled eight ‗hub gene-sets‘ (called Top25, Top50, so on till Top200), 
containing genes with ranks above the cut-off threshold, for each of the three parameters 
(Supplementary Information Table S1.1). Each of these hub gene-sets contains hub genes 
identified by either of the three parameters. Thus defined, the size of a hub gene-set may be up to 
three times the hub cut-off threshold, depending upon the similarity between the hubs identified by 
each of the parameters. Top25, Top50 and Top75 hub gene-sets of CGN contain 31, 60 and 92 
hub genes, respectively. Figure 3 depicts the CGN hub genes identified using Top75 hubs criterion. 
As a negative control for these hub gene-sets, we identified the corresponding genes (from the 
bottom of ranked lists), with lowest ranking for the chosen parameters. As random controls, we 
randomly sample a corresponding number of genes from CGN (1000 instances each). 
 
Compilation of genes involved in generic cancer mechanisms (KEGG-PIC) 
 
Cancer cell mechanisms could be envisaged as an elaborate integrated circuit of intracellular 
signaling networks [1,2]. This map of molecular mechanisms could be represented as a 
combination of circuits and subcircuits with considerable cross talk among them [1]. We compiled a 
set of (328) representative genes known to be implicated in generic cancer mechanisms from 
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cancer pathways/circuits (Supplementary Information Table S1.2). ‗Pathways in Cancer‘ (PIC) 
(hsa05200) from KEGG PATHWAY database, are representative of generic cancer circuits. Here, 
we call this ‗generic cancer genes‘ set KEGG-PIC [62]. KEGG-PIC comprise the following KEGG 
pathways: colorectal cancer (hsa05210), pancreatic cancer (hsa05212), thyroid cancer 
(hsa05216), acute myeloid leukemia (hsa05221), chronic myeloid leukemia (hsa05220), basal cell 
carcinoma (hsa05217), melanoma (hsa05218), renal cell carcinoma (hsa05211), bladder cancer 
(hsa05219), prostate cancer (hsa05215), endometrial cancer (hsa05213), small cell lung cancer 
(hsa05222), non-small cell lung cancer (hsa05223) and glioma (hsa05214). 
 
Mouse phenotype data 
 
For inferring the biological significance of the network parameters, we divided CGN into two sets, 
essential and non-essential, using the phenotypic information of the corresponding mouse ortholog 
[47,77]. It is assumed that human orthologs of mouse genes could be mapped onto each other for 
their function and biological essentiality. We considered the classes of embryonic, perinatal, 
neonatal or postnatal lethality in mouse models as lethal phenotypes, and the rest of the 
phenotypes as non-lethal ones. The human orthologs of murine genes were considered as 
essential, when the murine gene was annotated with one of the following phenotypes [63]: 
neonatal lethality (MP:0002058), embryonic lethality (MP:0002080), perinatal lethality 
(MP:0002081), postnatal lethality (MP:0002082), lethality-postnatal (MP:0005373), lethality-
embryonic/perinatal (MP:0005374), embryonic lethality before implantation (MP:0006204), 
embryonic lethality before somite formation (MP:0006205) or embryonic lethality before turning of 
embryo (MP:0006206). The human-mouse orthology and mouse phenotype data was obtained 
from Mouse Genome Informatics [65] (May 2012). Out of a total 2665 cancer genes of CGN, 1315 
(49.34%) were essential genes and the rest 1350 (50.66%) were non-essential. For each hub 
definition, from the hub-genes identified using each of the seven network metric, we compute the 
percentage of hubs that are essential (Figure 8A). We also found the percentage of essential 
genes in the corresponding non-hubs (Figure 8B). 
 
Venn diagram 
 
We logically juxtaposed the hubs of cancer genes network, curated bone cancer metastasis genes 
and cancer genes annotated with characteristic SBC GO terms to identify SBC-specific targets 
(Figure 2). Figure 10A illustrates this process highlighting the hubs of CGN (shaded area) that 
correspond to generic cancer genes and subsets potentially containing genes specific to SBC 
(hatched area). Figure 10B depicts the data when Top75 hubs of CGN are taken into 
consideration. For this data, there are 92 hubs of which 21 (Set-ab and Set-abc) happen to be 
common with SBCGs and 9 of those (Set-ac and Set-abc) are common to ‗enriched genes‘.  
Among the ‗secondary bone cancer enriched cancer genes‘ 55 are common to SBGCs (Set-bc and 
Set-abc). We find that, for this data, there are 2 genes (Set-abc) that happen to be CGN hubs that 
are common to SBCGs and are also annotated with characteristic SBC GO terms. The logical 
juxtaposition results for the data of Top25 and Top50 hubs of CGN are depicted in Figure 11A and 
Figure 11B, respectively. 
 
Prediction of SBC-specific candidate genes 
 
We propose that the genes that are specific to secondary bone cancer mechanisms would be 
annotated with characteristic GO terms that are obtained from overrepresentation analysis of a 
literature curated list of genes implicated in metastasis to bone. From the ‗secondary bone cancer 
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enriched cancer genes‘, that serve as a ‗source set of targets‘ we filtered the CGN hubs (Set-ac 
and Set-abc; shaded area) as they are generic to cancers (Figure 6) and found to be correlating 
with essential genes (Figure 8). Towards our aim of identifying SBC-specific targets, we focused on 
genes in Set-c and Set-bc (hatched area in Figure 10). We identified SBC-specific targets by 
refining these sets of genes to obtain genes that are annotated with any of the GO terms 
representing ‗bone processes‘ as well as that of ‗metastasis‘ (Figure 9) (Supplementary Information 
Table S1.4).   
 
SUPPORTING INFORMATION 
Supplementary Material S1. 
 
In the supplementary information we present the details of hubs of CGN; the KEGG-PIC genes that 
serve as a reference set of generic cancer genes; secondary bone cancer genes that were curated 
and compiled; characteristic GO terms that were used to obtain SBC-specific targets and 
relevance of SBC-specific targets identified from experimentally validated studies. The 
supplementary information contains 5 tables, out of which Table S1.3 has 46 references, Table 
S1.4 has 23 references and Table S1.5 has 8 references.  
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FIGURES:  
 
 
 
 
Figure 1. Regulatory mechanisms underlying metastasis to bone reflecting complex 
interplay of molecules.  
Bone metastasis results from imbalance of normal bone remodeling process involving osteolytic 
(leading to bone destruction) and osteoblastic (leading to aberrant bone formation) mechanisms. 
Breast cancer metastases are usually osteolytic, whereas prostate cancer metastases are usually 
osteoblastic. Osteolytic metastasis: Osteolytic metastasis of tumor cells involves a ―vicious cycle‖ 
between tumor cells and the skeleton. The vicious cycle is propagated by four contributors: tumor 
cells, bone-forming osteoblasts, bone resorbing osteoclasts and stored factors within bone matrix. 
Osteoclast formation and activity are regulated by the osteoblast, adding complexity to the vicious 
cycle. Tumor cells release certain factors including IL-1, IL-6, IL-8, IL-11, PTHrP and TNF that 
stimulate osteoclastic bone resorption. These factors enhance the expression of RANKL over OPG 
by osteoblasts, tipping the balance toward osteoclast activation thus causing bone resorption. This 
bone lysis stimulates the release of BMPs, TGFβ, IGFs and FGFs for stimulating the growth of 
metastatic cancer cells to bone. Osteoblastic metastasis: Factors released by osetoblastic cells, 
such as ET-1, Wnt, ERBB3, VEGF play an important role in osteoblastic metastasis by increasing 
cancer cell proliferation and enhance the effect of other growth factors including PDGF, FGFs, IGF-
1. Osteoblast differentiation is also increased by BMPs through the activation of certain 
transcription factors. Urokinase Plasminogen Activator (uPA), a protease, also acts as mediator for 
osteoblastic bone metastasis by cleaving osteoclast-mediated bone resorption factors responsible 
for regulation of osteoclast differentiation; thereby blocking the bone resorption. 
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Figure 2. Strategy implemented for the identification of targets specific to secondary bone 
cancer. 
The strategy that was implemented in this work comprised three tasks, leading to three 
corresponding gene-sets that were used for obtaining SBC-specific targets of potential therapeutic 
value. (a) A compilation of cancer genes from CancerGenes database was used to construct a 
representative cancer genes interactome (Cancer Genes Network; CGN) by mapping them on to a 
reference human protein interactome (Human Protein Reference Database; HPRD). Using 
methods of network analysis, proteins that are central to CGN and interaction dynamics were 
obtained. These set of genes (SET-A; shaded area) was found to be correlating well with genes 
implicated in generic cancer mechanisms (Figure 6) as well as those annotated as essential using 
mouse phenotype data (Figure 8). The CGN, comprising of 11602 interactions among 2665 
proteins, also serves as a reference set (universe) for gene enrichment studies; (b) A set of genes 
(Secondary Bone Cancer Genes; SBCGs) that are implicated in metastasis to bone from primary 
breast and prostate cancer, the most prevalent causes of bone metastasis, was compiled from 
literature. This set (SET-B) serves as a basis of genes and ontological correlates of secondary 
bone cancer that characterize the disease phenotype; (c) Significantly enriched GO terms that 
characterize SBCGs were obtained by overrepresentation analysis against the ‗cancer genes‘ 
universe. SET-C, a subset of CGN, was obtained by segregating cancer genes that were 
annotated with these SBC-specific ontological terms. Part of SET-C (hatched area; Set-c and Set-
bc in Figure 10A) serves as a ‗source set of target cancer genes‘ that, both, carry ontological 
essence of SBCGs and are not involved in generic cancer mechanisms. SBC-specific targets 
(Figure 3 and Figure 10B), that are annotated with key GO terms (Figure 9) reflecting role in, both, 
bone processes and metastasis mechanisms, were further obtained from the source set. 
22 
 
 
 
Figure 3. CGN, a representative protein interactome of cancer genes, Top75 hub genes and 
SBC-specific targets. Cancer Genes Network (CGN) is a protein interactome of cancer genes 
embodying molecular mechanisms of cancers. Each node represents a cancer protein and an 
edge between two nodes represents a protein-protein interaction. The giant cluster comprises 89% 
of all cancer genes. The hubs of CGN, cancer genes central to the structural stability and 
information dynamics, are depicted in shades of red. The hubs encode genes involved in generic 
cancer mechanisms and those classified as essential using phenotypic data from Mouse Genome 
Informatics. 88% of these hubs are essential (‗dark red‘) and the rest non-essential (‗light red‘). 
SBC-specific targets, with ontological role in bone and metastasis processes, are highlighted in 
‗green‘. 
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Figure 4. Scale-free nature of degree and betweenness distributions of CGN. 
The distributions of (A) degree and (B) stress (as well as its normalized counterpart ‗betweenness‘) 
show a scale-free nature. Dotted lines show the power law fit with an exponent of -2.85 and -2.13, 
respectively. This indicates presence of promiscuously interacting proteins with high degrees and 
central mediators that play role in information dynamics across the network, respectively.  
 
 
Figure 5. Heatmap of topological metrics computed for Cancer Genes Network. 
The heatmap of pair-wise correlations among seven parameters that enumerate topological, 
dynamical and local clustering features of the network: betweenness, stress, degree, neighborhood 
connectivity (neigh_conn), clustering coefficient (clust_coeff), average shortest path length 
(avg_short_paths) and topological coefficient (topo_coeff). The heatmap highlights three 
parameters with very high mutual positive correlations (r=0.8989, 0.9930 and 0.9210): degree, 
betweenness and stress. The upper triangle of the heatmap depicts pair-wise correlations as pie 
charts. The lower triangle depicts positive and negative correlations in shades of blue and red, 
respectively; the darker the color the stronger the correlation. Positive and negative correlations 
are also depicted with right- and left-handed diagonal lines. 
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Figure 6. Hubs of CGN correlate with generic cancer genes (KEGG-PIC).   
The hubs of CGN, identified using chosen network centrality parameters, correlate with the set of 
generic cancer genes (KEGG-PIC). For hub definitions varying between Top25—Top200, the CGN 
hubs (top ranked cancer genes) show good overlap with KEGG-PIC genes (filled circles). The 
correspondence of network centrality and generic role in cancers, expectedly, drops as the 
strictness of criterion used for identifying hubs is loosened. For the corresponding random 
samples, the overlap with KEGG-PIC is as expected (stars; error bars indicate standard errors 
from 1000 samples). The cancer genes with worst centrality rankings (open circles), show almost 
no overlap with generic cancer genes; worse than that expected from random samplings. Top75, 
Top50 and Top25 hubs, with 52%, 57% and 74% overlap with generic cancer genes, respectively, 
were further used for identification of SBC-specific cancer genes. 
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Figure 7. Significantly enriched GO terms for hubs of CGN reflecting their role in generic 
cancer mechanisms.  
The overrepresentation studies of Top75 CGN hubs reflect their role in generic cancer processes 
and functions. Among the significantly enriched GO terms, 17 represent self-proliferation circuits 
(light-gray), 20 represent cytostasis and differentiation circuits (dark gray) and 4 represent viability 
circuits (black). 
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Figure 8. The percentage of essential genes in the hubs and the corresponding non-hubs of 
CGN.  
A. For hub definitions varying between Top25 to Top200, the hubs identified using degree (1, ‗red‘), 
betweenness (2, ‘green‘), and stress (3, ‗blue‘) have significantly high percentage (82%—92%) of 
essential genes, classified using phenotypic data for Mouse Genome Informatics. Among the rest 
of the four parameters neighborhood connectivity (4) and topological coefficient (5) show neither 
significant nor consistent correlation with essential genes. Due to the nature of ‗clustering 
coefficient‘ and ‗average shortest path length‘ parameters, the data could not be binned at the 
same intervals. For clustering coefficient, percentage of essential genes among the nodes having 
up to Top200 rankings is in the range of 27% and 62%. For average shortest path length, the 
percentage of essential genes for nodes having ranking up to Top200 is 26%, worse than expected 
from random sampling. B. In the corresponding non-hubs, the percentage of essential genes is as 
expected from random sampling, regardless of the centrality measure or cut-off used for hub 
definition. 
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Figure 9. Overrepresented GO terms of processes relevant and necessary for execution of 
bone metastasis. 
From the GO enrichment studies of SBCGs, curated from literature, 21 GO terms relevant for 
metastasis (‗light gray‘) and 10 GO terms relevant for bone (‗dark gray‘) processes were identified. 
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Figure 10. Venn diagrams depicting the strategy used for the identification of SBC-specific 
targets.  
A. Venn diagram legend representing generic cancer genes identified by network analysis (CGN 
hub genes; gray area) and gene subsets used as a source of target genes that are specific to bone 
metastasis (hatched area). In search of SBC-specific targets, the generic cancer genes were 
rejected and the potential source of target genes was refined to obtain the final targets. B. Venn 
diagram depicting components of gene-sets identified using Top75 hubs. The source set of target 
genes (53+134) was refined to obtain seven targets.   
 
 
 
Figure 11. Venn diagram of gene sets obtained with Top25 and Top50 CGN hubs. The Venn 
diagrams with generic gene-set (gray area) and source set of target genes (hatched area) for (A) 
Top25 and (B) Top50 CGN hubs. 
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SUMMARY 
In the supplementary information we present the details of hubs of CGN; the KEGG-PIC genes that 
serve as a reference set of generic cancer genes; secondary bone cancer genes that were curated 
and compiled; characteristic GO terms that were used to obtain SBC-specific targets and 
relevance of SBC-specific targets identified from experimentally validated studies. The 
supplementary information contains 5 tables, out of which Table S1.3 has 46 references, Table 
S1.4 has 23 references and Table S1.5 has 8 references.  
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Table S1.1. Hub genes (Top25—Top200) of Cancer Genes Network. 
Top25 
hubs (31) 
Top50  
hubs (60) 
Top75  
hubs (92) 
Top100  
hubs (125) 
Top125  
hubs (158) 
Top150  
hubs (185) 
Top175 
hubs (213) 
Top200 
hubs 
(247) 
ABL1 ABL1 ABL1 ABL1 ABL1 ABL1 ABL1 ABL1 
AKT1 AKT1 ACTB ACTB ACTB ACTB ACTB ACTB 
AR AR AKT1 AKT1 AKT1 AKT1 ACVR1 ACVR1 
BRCA1 BCL2 APP APP APP APP AKT1 AKT1 
CASP3 BRCA1 AR AR AR AR APP APP 
CREBBP CASP3 BCL2 BCL2 AXIN1 ATM AR AR 
CSNK2A1 CAV1 BRCA1 BRCA1 BCL2 AXIN1 ATM ATF2 
CTNNB1 CBL CASP3 CASP3 BRCA1 BAT3 AXIN1 ATM 
EGFR CDK2 CASP8 CASP8 BTK BCL2 BAT3 AXIN1 
EP300 CREBBP CAV1 CAV1 CALR BCR BCAR1 BAD 
ESR1 CSNK2A1 CBL CBL CASP3 BRCA1 BCL2 BAT3 
FYN CTNNB1 CDK2 CDK2 CASP8 BTK BCR BCAR1 
GRB2 DLG4 CHUK CDKN1A CAV1 CADM1 BIRC2 BCL2 
HDAC1 EGFR CREBBP CDKN1B CBL CALR BRCA1 BCR 
JUN EP300 CRK CEBPB CCNB1 CASP3 BRCA2 BIRC2 
MAPK1 ESR1 CSNK2A1 CHUK CCND1 CASP8 BTK BMPR1B 
MAPK3 FLNA CTNNB1 CREBBP CDC42 CAV1 CADM1 BRCA1 
PRKACA FYN DLG4 CRK CDK2 CBL CALR BRCA2 
PRKCA GRB2 EEF1A1 CSNK2A1 CDK9 CCNB1 CASP3 BTK 
RAF1 GSK3B EGFR CSNK2A2 CDKN1A CCND1 CASP8 BTRC 
RB1 HDAC1 EP300 CTNNB1 CDKN1B CDC42 CAV1 CADM1 
RELA HSP90AA1 ESR1 DLG4 CEBPB CDK2 CBL CALR 
SMAD2 INSR EWSR1 DYNLL1 CHUK CDK4 CCNB1 CASP3 
SMAD3 JAK2 FLNA EEF1A1 CREBBP CDK9 CCND1 CASP8 
SMAD4 JUN FYN EGFR CRK CDKN1A CDC42 CAV1 
SRC LCK GNAI2 EP300 CRKL CDKN1B CDK2 CBL 
STAT3 LYN GRB2 EPHB2 CSNK2A1 CEBPB CDK4 CCNB1 
TGFBR1 MAPK1 GSK3B ERBB2 CSNK2A2 CHUK CDK9 CCND1 
TP53 MAPK14 HDAC1 ESR1 CTNNB1 CREB1 CDKN1A CD44 
YWHAG MAPK3 HRAS EWSR1 DAXX CREBBP CDKN1B CDC42 
YWHAZ NFKB1 HSP90AA1 FLNA DLG4 CRK CEBPB CDH1 
  NR3C1 IGF1R FOS DYNLL1 CRKL CHUK CDK2 
  PAK1 INSR FYN EEF1A1 CSK CREB1 CDK4 
  PCNA IRS1 GNAI2 EGFR CSNK2A1 CREBBP CDK9 
  PLCG1 JAK1 GRB2 EP300 CSNK2A2 CRK CDKN1A 
  PRKACA JAK2 GSK3B EPB41L3 CTNNB1 CRKL CDKN1B 
  PRKCA JUN HDAC1 EPHB2 DAXX CSK CDKN2A 
  PRKCD KAT5 HDAC2 ERBB2 DLG4 CSNK2A1 CEBPB 
  PTK2 KIT HIF1A ESR1 DYNLL1 CSNK2A2 CHD3 
  PTPN11 LCK HMGB1 EWSR1 E2F1 CTNNB1 CHUK 
  RAF1 LRP1 HRAS FLNA EEF1A1 DAXX CREB1 
  RB1 LYN HSP90AA1 FN1 EGFR DLG4 CREBBP 
  RELA MAPK1 HTT FOS EP300 DYNLL1 CRK 
31 
 
  SMAD2 MAPK14 IGF1R FYN EPB41L3 E2F1 CRKL 
  SMAD3 MAPK3 IKBKB GNAI2 EPHB2 EEF1A1 CSK 
  SMAD4 MAPK8 IKBKG GNB2L1 ERBB2 EGFR CSNK2A1 
  SP1 MDM2 INSR GRB2 ESR1 EP300 CSNK2A2 
  SRC MYC IRS1 GSK3B ESR2 EPB41L3 CSNK2B 
  STAT1 NCK1 JAK1 HCK EWSR1 EPHB2 CTNNB1 
  STAT3 NFKB1 JAK2 HDAC1 FLNA EPOR DAXX 
  TGFBR1 NFKBIA JUN HDAC2 FN1 ERBB2 DLG4 
  TP53 NOTCH1 KAT5 HDAC3 FOS ESR1 DOK1 
  TRAF2 NR3C1 KIT HIF1A FYN ESR2 DVL1 
  TRAF6 PAK1 LCK HIPK2 GNAI2 ETS1 DYNLL1 
  UBB PCNA LRP1 HMGB1 GNB2L1 EWSR1 E2F1 
  UBE2I PLCG1 LYN HRAS GRB2 FGFR1 EEF1A1 
  VIM PML MAPK1 HSP90AA1 GSK3B FLNA EGFR 
  YWHAB PRKACA MAPK14 HSPA1A HCK FN1 EP300 
  YWHAG PRKCA MAPK3 HTT HDAC1 FOS EPB41 
  YWHAZ PRKCD MAPK8 IGF1R HDAC2 FYN EPB41L3 
    PRKCZ MDM2 IKBKB HDAC3 GNA13 EPHB2 
    PTK2 MYC IKBKG HIF1A GNAI2 EPOR 
    PTK2B NCK1 INSR HIPK2 GNB2L1 ERBB2 
    PTPN11 NCOA1 IRS1 HMGB1 GRB2 ERBB4 
    PTPN6 NCOR2 JAK1 HRAS GSK3B ESR1 
    RAC1 NFKB1 JAK2 HSP90AA1 HCK ESR2 
    RAF1 NFKBIA JUN HSPA1A HDAC1 ETS1 
    RASA1 NFKBIB KAT2B HTT HDAC2 EWSR1 
    RB1 NOTCH1 KAT5 IGF1R HDAC3 FADD 
    RELA NR3C1 KIT IKBKB HIF1A FGFR1 
    SMAD1 PAK1 LCK IKBKG HIPK2 FLNA 
    SMAD2 PCNA LRP1 INSR HMGB1 FN1 
    SMAD3 PDGFRB LYN IRS1 HRAS FOS 
    SMAD4 PIN1 MAP3K7 ITGB1 HSP90AA1 FYN 
    SP1 PLCG1 MAPK1 JAK1 HSPA1A GNA13 
    SRC PML MAPK14 JAK2 HTT GNAI2 
    STAT1 POLR2A MAPK3 JUN IGF1R GNB2L1 
    STAT3 PRKACA MAPK8 KAT2B IGF2 GRB2 
    SUMO4 PRKCA MBP KAT5 IKBKB GSK3B 
    SYK PRKCD MDM2 KDR IKBKG HCK 
    TGFBR1 PRKCZ MET KIT INSR HDAC1 
    TP53 PTCH1 MYC LCK IRS1 HDAC2 
    TRAF2 PTEN MYOD1 LRP1 ITGB1 HDAC3 
    TRAF6 PTK2 NCK1 LYN ITGB4 HGS 
    UBB PTK2B NCOA1 MAP3K14 JAK1 HIF1A 
    UBE2I PTPN11 NCOA3 MAP3K7 JAK2 HIPK2 
    VAV1 PTPN6 NCOR1 MAPK1 JUN HMGB1 
    VIM RAC1 NCOR2 MAPK14 KAT2B HRAS 
    YWHAB RAD51 NFKB1 MAPK3 KAT5 HSP90AA
1 
    YWHAG RAF1 NFKBIA MAPK8 KDR HSPA1A 
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    YWHAZ RASA1 NFKBIB MAPT KHDRBS1 HTT 
    ZBTB16 RB1 NOTCH1 MBP KIT IGF1R 
      RELA NR3C1 MDM2 KPNB1 IGF2 
      RXRA PAK1 MET KRT18 IKBKB 
      SIN3A PCNA MYC LCK IKBKG 
      SMAD1 PDGFRB MYOD1 LRP1 IL6ST 
      SMAD2 PIAS1 NCK1 LRP6 INSR 
      SMAD3 PIN1 NCOA1 LYN IRAK1 
      SMAD4 PLCG1 NCOA3 MAP3K14 IRS1 
      SMURF2 PML NCOR1 MAP3K5 IRS2 
      SP1 POLR2A NCOR2 MAP3K7 ITGB1 
      SRC PPP2CA NDRG1 MAPK1 ITGB3 
      STAT1 PRKACA NFKB1 MAPK14 ITGB4 
      STAT3 PRKAR2A NFKBIA MAPK3 JAK1 
      STAT5A PRKCA NFKBIB MAPK8 JAK2 
      SUMO1 PRKCD NOTCH1 MAPK9 JUN 
      SUMO4 PRKCZ NR3C1 MAPT KAT2B 
      SVIL PTCH1 PAK1 MBP KAT5 
      SYK PTEN PCNA MDM2 KDR 
      TBP PTK2 PDGFRB MET KHDRBS1 
      TGFBR1 PTK2B PIAS1 MMP2 KIT 
      TNFRSF1A PTPN11 PIN1 MYC KPNB1 
      TP53 PTPN6 PLCG1 MYOD1 KRT18 
      TRAF2 PTPRC PLSCR1 NCK1 LCK 
      TRAF6 RAC1 PML NCOA1 LRP1 
      UBB RAD51 POLR2A NCOA2 LRP6 
      UBE2I RAF1 PPP2CA NCOA3 LYN 
      VAV1 RASA1 PRKAA1 NCOR1 MAP2K1 
      VIM RB1 PRKACA NCOR2 MAP3K14 
      XRCC6 RELA PRKAR2A NDRG1 MAP3K5 
      YWHAB RET PRKCA NFKB1 MAP3K7 
      YWHAG RHOA PRKCD NFKBIA MAPK1 
      YWHAH RXRA PRKCZ NFKBIB MAPK14 
      YWHAZ SIN3A PRKDC NOTCH1 MAPK3 
      ZBTB16 SMAD1 PSEN1 NR3C1 MAPK8 
        SMAD2 PTCH1 PAK1 MAPK9 
        SMAD3 PTEN PCNA MAPT 
        SMAD4 PTK2 PDGFRB MBP 
        SMURF2 PTK2B PDPK1 MDM2 
        SP1 PTPN1 PIAS1 MET 
        SRC PTPN11 PIN1 MITF 
        STAT1 PTPN6 PLCG1 MLLT4 
        STAT3 PTPRC PLSCR1 MMP2 
        STAT5A RAC1 PML MMP9 
        STAT5B RAD51 POLR2A MPP3 
        SUMO1 RAF1 PPP2CA MYC 
        SUMO4 RARA PPP2R1B MYOD1 
        SVIL RASA1 PRKAA1 NCK1 
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        SYK RB1 PRKACA NCOA1 
        TBP RELA PRKAR2A NCOA2 
        TGFBR1 RET PRKCA NCOA3 
        TNFRSF1A RHOA PRKCD NCOA6 
        TP53 RXRA PRKCZ NCOR1 
        TRAF2 SIN3A PRKDC NCOR2 
        TRAF6 SKP1 PSEN1 NDRG1 
        TUBB SMAD1 PTCH1 NFKB1 
        UBB SMAD2 PTEN NFKBIA 
        UBE2I SMAD3 PTK2 NFKBIB 
        VAV1 SMAD4 PTK2B NGFR 
        VIM SMURF2 PTPN1 NOTCH1 
        XRCC6 SOCS1 PTPN11 NR3C1 
        YWHAB SOS1 PTPN6 PAK1 
        YWHAE SP1 PTPRC PARP1 
        YWHAG SRC RAC1 PCNA 
        YWHAH STAT1 RAD51 PDGFRB 
        YWHAQ STAT3 RAF1 PDPK1 
        YWHAZ STAT5A RARA PIAS1 
        ZBTB16 STAT5B RASA1 PIK3R2 
          SUMO1 RB1 PIN1 
          SUMO4 RELA PLCG1 
          SVIL RET PLSCR1 
          SYK RHOA PML 
          TBP RUNX1 POLR2A 
          TGFBR1 RXRA PPP2CA 
          TNFRSF1A SIN3A PPP2R1B 
          TP53 SKIL PRKAA1 
          TP73 SKP1 PRKACA 
          TRAF2 SMAD1 PRKAR2A 
          TRAF6 SMAD2 PRKCA 
          TSC2 SMAD3 PRKCD 
          TUBB SMAD4 PRKCZ 
          UBB SMAD7 PRKDC 
          UBE2I SMARCA4 PSEN1 
          VAV1 SMURF1 PTCH1 
          VIM SMURF2 PTEN 
          XPO1 SNCA PTK2 
          XRCC6 SOCS1 PTK2B 
          YWHAB SOS1 PTPN1 
          YWHAE SP1 PTPN11 
          YWHAG SRC PTPN6 
          YWHAH STAT1 PTPRC 
          YWHAQ STAT3 RAC1 
          YWHAZ STAT5A RAD51 
          ZAP70 STAT5B RAF1 
          ZBTB16 SUMO1 RARA 
            SUMO4 RASA1 
34 
 
            SVIL RB1 
            SYK RBL1 
            TBP RELA 
            TCF3 RELB 
            TGFBR1 RET 
            TNFRSF1
A 
RHOA 
            TP53 RIPK1 
            TP73 RUNX1 
            TRAF2 RXRA 
            TRAF6 SIN3A 
            TSC2 SKIL 
            TUBB SKP1 
            UBB SKP2 
            UBE2I SMAD1 
            VAV1 SMAD2 
            VHL SMAD3 
            VIM SMAD4 
            XPO1 SMAD7 
            XRCC6 SMARCA
4 
            YWHAB SMURF1 
            YWHAE SMURF2 
            YWHAG SNCA 
            YWHAH SOCS1 
            YWHAQ SOS1 
            YWHAZ SP1 
            ZAP70 SRC 
            ZBTB16 STAT1 
              STAT3 
              STAT5A 
              STAT5B 
              SUMO1 
              SUMO4 
              SVIL 
              SYK 
              TBP 
              TCF3 
              TERT 
              TGFBR1 
              TGFBR2 
              TNFRSF1
A 
              TP53 
              TP73 
              TRAF2 
              TRAF6 
              TSC2 
              TUBB 
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              UBB 
              UBE2I 
              VAV1 
              VHL 
              VIM 
              XPO1 
              XRCC6 
              YWHAB 
              YWHAE 
              YWHAG 
              YWHAH 
              YWHAQ 
              YWHAZ 
              ZAP70 
              ZBTB16 
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Table S1.2. Details of KEGG-PIC genes (328) from KEGG PATHWAY Database. 
HGNC Gene 
ID 
Gene Symbol Full Name of the Gene 
1630   DCC  deleted in colorectal carcinoma  
836   CASP3  caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56)  
842   CASP9  caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62)  
26060   APPL1  adaptor protein, phosphotyrosine interaction, PH domain and leucine 
zipper containing 1  
999   CDH1  cadherin 1, type 1, E-cadherin (epithelial)  
1499   CTNNB1  catenin (cadherin-associated protein), beta 1, 88kDa  
1496   CTNNA2  catenin (cadherin-associated protein), alpha 2  
1495   CTNNA1  catenin (cadherin-associated protein), alpha 1, 102kDa  
29119   CTNNA3  catenin (cadherin-associated protein), alpha 3  
8312   AXIN1  axin 1  
8313   AXIN2  axin 2  
10297   APC2  adenomatosis polyposis coli 2  
324   APC  adenomatous polyposis coli  
2932   GSK3B  glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26)  
6932   TCF7  transcription factor 7 (T-cell specific, HMG-box)  
83439   TCF7L1  transcription factor 7-like 1 (T-cell specific, HMG-box)  
6934   TCF7L2  transcription factor 7-like 2 (T-cell specific, HMG-box)  
51176   LEF1  lymphoid enhancer-binding factor 1  
332   BIRC5  baculoviral IAP repeat containing 5  
4609   MYC  v-myc myelocytomatosis viral oncogene homolog (avian)  
595   CCND1  cyclin D1  
7471   WNT1  wingless-type MMTV integration site family, member 1  
7482   WNT2B  wingless-type MMTV integration site family, member 2B  
7472   WNT2  wingless-type MMTV integration site family member 2  
7473   WNT3  wingless-type MMTV integration site family, member 3  
89780   WNT3A  wingless-type MMTV integration site family, member 3A  
54361   WNT4  wingless-type MMTV integration site family, member 4  
7474   WNT5A  wingless-type MMTV integration site family, member 5A  
81029   WNT5B  wingless-type MMTV integration site family, member 5B  
7475   WNT6  wingless-type MMTV integration site family, member 6  
7477   WNT7B  wingless-type MMTV integration site family, member 7B  
7476   WNT7A  wingless-type MMTV integration site family, member 7A  
7479   WNT8B  wingless-type MMTV integration site family, member 8B  
7478   WNT8A  wingless-type MMTV integration site family, member 8A  
7483   WNT9A  wingless-type MMTV integration site family, member 9A  
7484   WNT9B  wingless-type MMTV integration site family, member 9B  
7480   WNT10B  wingless-type MMTV integration site family, member 10B  
80326   WNT10A  wingless-type MMTV integration site family, member 10A  
7481   WNT11  wingless-type MMTV integration site family, member 11  
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51384   WNT16  wingless-type MMTV integration site family, member 16  
8321   FZD1  frizzled family receptor 1  
8324   FZD7  frizzled family receptor 7  
2535   FZD2  frizzled family receptor 2  
7976   FZD3  frizzled family receptor 3  
8322   FZD4  frizzled family receptor 4  
8325   FZD8  frizzled family receptor 8  
7855   FZD5  frizzled family receptor 5  
8323   FZD6  frizzled family receptor 6  
8326   FZD9  frizzled family receptor 9  
11211   FZD10  frizzled family receptor 10  
1856   DVL2  dishevelled, dsh homolog 2 (Drosophila)  
1857   DVL3  dishevelled, dsh homolog 3 (Drosophila)  
1855   DVL1  dishevelled, dsh homolog 1 (Drosophila)  
1284   COL4A2  collagen, type IV, alpha 2  
1286   COL4A4  collagen, type IV, alpha 4  
1288   COL4A6  collagen, type IV, alpha 6  
1287   COL4A5  collagen, type IV, alpha 5  
1282   COL4A1  collagen, type IV, alpha 1  
284217   LAMA1  laminin, alpha 1  
3908   LAMA2  laminin, alpha 2  
3911   LAMA5  laminin, alpha 5  
3909   LAMA3  laminin, alpha 3  
3910   LAMA4  laminin, alpha 4  
3912   LAMB1  laminin, beta 1  
3913   LAMB2  laminin, beta 2 (laminin S)  
3914   LAMB3  laminin, beta 3  
22798   LAMB4  laminin, beta 4  
3915   LAMC1  laminin, gamma 1 (formerly LAMB2)  
3918   LAMC2  laminin, gamma 2  
10319   LAMC3  laminin, gamma 3  
2335   FN1  fibronectin 1  
3673   ITGA2  integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)  
3674   ITGA2B  integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen 
CD41)  
3675   ITGA3  integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)  
3655   ITGA6  integrin, alpha 6  
3685   ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen 
CD51)  
3688   ITGB1  integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 
includes MDF2, MSK12)  
5747   PTK2  PTK2 protein tyrosine kinase 2 (EC:2.7.10.2)  
5293   PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide (EC:2.7.1.153)  
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5291   PIK3CB  phosphoinositide-3-kinase, catalytic, beta polypeptide (EC:2.7.1.153)  
5294   PIK3CG  phosphoinositide-3-kinase, catalytic, gamma polypeptide (EC:2.7.11.1 
2.7.1.153)  
5290   PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide (EC:2.7.11.1 
2.7.1.153)  
8503   PIK3R3  phosphoinositide-3-kinase, regulatory subunit 3 (gamma)  
23533   PIK3R5  phosphoinositide-3-kinase, regulatory subunit 5  
5296   PIK3R2  phosphoinositide-3-kinase, regulatory subunit 2 (beta)  
5295   PIK3R1  phosphoinositide-3-kinase, regulatory subunit 1 (alpha)  
5728   PTEN  phosphatase and tensin homolog (EC:3.1.3.67 3.1.3.16 3.1.3.48)  
4824   NKX3-1  NK3 homeobox 1  
207   AKT1  v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1)  
208   AKT2  v-akt murine thymoma viral oncogene homolog 2 (EC:2.7.11.1)  
10000   AKT3  v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma) (EC:2.7.11.1)  
1147   CHUK  conserved helix-loop-helix ubiquitous kinase (EC:2.7.11.10)  
3551   IKBKB  inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase 
beta (EC:2.7.11.10)  
8517   IKBKG  inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase 
gamma  
4792   NFKBIA  nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha  
4790   NFKB1  nuclear factor of kappa light polypeptide gene enhancer in B-cells 1  
4791   NFKB2  nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 
(p49/p100)  
5970   RELA  v-rel reticuloendotheliosis viral oncogene homolog A (avian)  
5743   PTGS2  prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) (EC:1.14.99.1)  
4843   NOS2  nitric oxide synthase 2, inducible (EC:1.14.13.39)  
596   BCL2  B-cell CLL/lymphoma 2  
330   BIRC3  baculoviral IAP repeat containing 3  
331   XIAP  X-linked inhibitor of apoptosis  
329   BIRC2  baculoviral IAP repeat containing 2  
598   BCL2L1  BCL2-like 1  
7185   TRAF1  TNF receptor-associated factor 1  
7186   TRAF2  TNF receptor-associated factor 2  
7187   TRAF3  TNF receptor-associated factor 3  
9618   TRAF4  TNF receptor-associated factor 4  
7188   TRAF5  TNF receptor-associated factor 5  
7189   TRAF6  TNF receptor-associated factor 6, E3 ubiquitin protein ligase  
2475   MTOR  mechanistic target of rapamycin (serine/threonine kinase) 
(EC:2.7.11.1)  
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572   BAD  BCL2-associated agonist of cell death  
2308   FOXO1  forkhead box O1  
4193   MDM2  Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse) (EC:6.3.2.19) 
7157   TP53  tumor protein p53  
1027   CDKN1B  cyclin-dependent kinase inhibitor 1B (p27, Kip1)  
1026   CDKN1A  cyclin-dependent kinase inhibitor 1A (p21, Cip1)  
613   BCR  breakpoint cluster region (EC:2.7.11.1)  
25   ABL1  c-abl oncogene 1, non-receptor tyrosine kinase (EC:2.7.10.2)  
1399   CRKL  v-crk sarcoma virus CT10 oncogene homolog (avian)-like  
1398   CRK  v-crk sarcoma virus CT10 oncogene homolog (avian)  
23624   CBLC  Cbl proto-oncogene, E3 ubiquitin protein ligase C (EC:6.3.2.19) 
868   CBLB  Cbl proto-oncogene, E3 ubiquitin protein ligase B (EC:6.3.2.19) 
867   CBL  Cbl proto-oncogene, E3 ubiquitin protein ligase (EC:6.3.2.19) 
6776   STAT5A  signal transducer and activator of transcription 5A  
6777   STAT5B  signal transducer and activator of transcription 5B  
3716   JAK1  Janus kinase 1 (EC:2.7.10.2)  
6774   STAT3  signal transducer and activator of transcription 3 (acute-phase 
response factor)  
6772   STAT1  signal transducer and activator of transcription 1, 91kDa  
7423   VEGFB  vascular endothelial growth factor B  
5228   PGF  placental growth factor  
7422   VEGFA  vascular endothelial growth factor A  
7424   VEGFC  vascular endothelial growth factor C  
2277   FIGF  c-fos induced growth factor (vascular endothelial growth factor D)  
7039   TGFA  transforming growth factor, alpha  
1950   EGF  epidermal growth factor  
1956   EGFR  epidermal growth factor receptor (EC:2.7.10.1)  
2064   ERBB2  v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) (EC:2.7.10.1)  
5154   PDGFA  platelet-derived growth factor alpha polypeptide  
5155   PDGFB  platelet-derived growth factor beta polypeptide  
5156   PDGFRA  platelet-derived growth factor receptor, alpha polypeptide 
(EC:2.7.10.1)  
5159   PDGFRB  platelet-derived growth factor receptor, beta polypeptide (EC:2.7.10.1)  
3479   IGF1  insulin-like growth factor 1 (somatomedin C)  
3480   IGF1R  insulin-like growth factor 1 receptor (EC:2.7.10.1)  
4254   KITLG  KIT ligand  
3815   KIT  v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
(EC:2.7.10.1)  
40 
 
2323   FLT3LG  fms-related tyrosine kinase 3 ligand  
2322   FLT3  fms-related tyrosine kinase 3 (EC:2.7.10.1)  
3082   HGF  hepatocyte growth factor (hepapoietin A  
4233   MET  met proto-oncogene (hepatocyte growth factor receptor) (EC:2.7.10.1)  
2258   FGF13  fibroblast growth factor 13  
2253   FGF8  fibroblast growth factor 8 (androgen-induced)  
8817   FGF18  fibroblast growth factor 18  
2257   FGF12  fibroblast growth factor 12  
2248   FGF3  fibroblast growth factor 3  
2251   FGF6  fibroblast growth factor 6  
2256   FGF11  fibroblast growth factor 11  
8823   FGF16  fibroblast growth factor 16  
2252   FGF7  fibroblast growth factor 7  
2259   FGF14  fibroblast growth factor 14  
8822   FGF17  fibroblast growth factor 17  
9965   FGF19  fibroblast growth factor 19  
2254   FGF9  fibroblast growth factor 9 (glia-activating factor)  
2250   FGF5  fibroblast growth factor 5  
2249   FGF4  fibroblast growth factor 4  
8074   FGF23  fibroblast growth factor 23  
27006   FGF22  fibroblast growth factor 22  
26281   FGF20  fibroblast growth factor 20  
2255   FGF10  fibroblast growth factor 10  
2247   FGF2  fibroblast growth factor 2 (basic)  
26291   FGF21  fibroblast growth factor 21  
2246   FGF1  fibroblast growth factor 1 (acidic)  
2260   FGFR1  fibroblast growth factor receptor 1 (EC:2.7.10.1)  
2263   FGFR2  fibroblast growth factor receptor 2 (EC:2.7.10.1)  
2261   FGFR3  fibroblast growth factor receptor 3 (EC:2.7.10.1)  
2885   GRB2  growth factor receptor-bound protein 2  
6654   SOS1  son of sevenless homolog 1 (Drosophila)  
6655   SOS2  son of sevenless homolog 2 (Drosophila)  
3265   HRAS  v-Ha-ras Harvey rat sarcoma viral oncogene homolog  
3845   KRAS  v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
4893   NRAS  neuroblastoma RAS viral (v-ras) oncogene homolog  
369   ARAF  v-raf murine sarcoma 3611 viral oncogene homolog (EC:2.7.11.1)  
673   BRAF  v-raf murine sarcoma viral oncogene homolog B1 (EC:2.7.11.1)  
5894   RAF1  v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1)  
5604   MAP2K1  mitogen-activated protein kinase kinase 1 (EC:2.7.12.2)  
5605   MAP2K2  mitogen-activated protein kinase kinase 2 (EC:2.7.12.2)  
5594   MAPK1  mitogen-activated protein kinase 1 (EC:2.7.11.24)  
5595   MAPK3  mitogen-activated protein kinase 3 (EC:2.7.11.24)  
3725   JUN  jun proto-oncogene  
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2353   FOS  FBJ murine osteosarcoma viral oncogene homolog  
4312   MMP1  matrix metallopeptidase 1 (interstitial collagenase) (EC:3.4.24.7)  
4313   MMP2  matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa 
type IV collagenase) (EC:3.4.24.24)  
4318   MMP9  matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) (EC:3.4.24.35)  
3576   IL8  interleukin 8  
1019   CDK4  cyclin-dependent kinase 4 (EC:2.7.11.22)  
5979   RET  ret proto-oncogene (EC:2.7.10.1)  
8030   CCDC6  coiled-coil domain containing 6  
8031   NCOA4  nuclear receptor coactivator 4  
4914   NTRK1  neurotrophic tyrosine kinase, receptor, type 1 (EC:2.7.10.1)  
7170   TPM3  tropomyosin 3  
7175   TPR  translocated promoter region (to activated MET oncogene)  
10342   TFG  TRK-fused gene  
11186   RASSF1  Ras association (RalGDS/AF-6) domain family member 1  
83593   RASSF5  Ras association (RalGDS/AF-6) domain family member 5  
6789   STK4  serine/threonine kinase 4 (EC:2.7.11.1)  
1613   DAPK3  death-associated protein kinase 3 (EC:2.7.11.1)  
23604   DAPK2  death-associated protein kinase 2 (EC:2.7.11.1)  
1612   DAPK1  death-associated protein kinase 1 (EC:2.7.11.1)  
5335   PLCG1  phospholipase C, gamma 1 (EC:3.1.4.11)  
5336   PLCG2  phospholipase C, gamma 2 (phosphatidylinositol-specific) 
(EC:3.1.4.11)  
5579   PRKCB  protein kinase C, beta (EC:2.7.11.13)  
5578   PRKCA  protein kinase C, alpha (EC:2.7.11.13)  
5582   PRKCG  protein kinase C, gamma (EC:2.7.11.13)  
5900   RALGDS  ral guanine nucleotide dissociation stimulator  
5898   RALA  v-ral simian leukemia viral oncogene homolog A (ras related)  
5899   RALB  v-ral simian leukemia viral oncogene homolog B (ras related  
10928   RALBP1  ralA binding protein 1  
998   CDC42  cell division cycle 42 (GTP binding protein, 25kDa)  
5879   RAC1  ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1)  
5880   RAC2  ras-related C3 botulinum toxin substrate 2 (rho family, small GTP 
binding protein Rac2)  
5881   RAC3  ras-related C3 botulinum toxin substrate 3 (rho family, small GTP 
binding protein Rac3)  
387   RHOA  ras homolog family member A  
5602   MAPK10  mitogen-activated protein kinase 10 (EC:2.7.11.24)  
5601   MAPK9  mitogen-activated protein kinase 9 (EC:2.7.11.24)  
5599   MAPK8  mitogen-activated protein kinase 8 (EC:2.7.11.24)  
7849   PAX8  paired box 8  
5468   PPARG  peroxisome proliferator-activated receptor gamma  
6256   RXRA  retinoid X receptor, alpha  
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6257   RXRB  retinoid X receptor, beta  
6258   RXRG  retinoid X receptor, gamma  
5915   RARB  retinoic acid receptor, beta  
5467   PPARD  peroxisome proliferator-activated receptor delta  
3728   JUP  junction plakoglobin  
7704   ZBTB16  zinc finger and BTB domain containing 16  
5371   PML  promyelocytic leukemia  
5914   RARA  retinoic acid receptor, alpha  
861   RUNX1  runt-related transcription factor 1  
862   RUNX1T1  runt-related transcription factor 1  
6688   SPI1  spleen focus forming virus (SFFV) proviral integration oncogene spi1  
1050   CEBPA  CCAAT/enhancer binding protein (C/EBP), alpha  
1438   CSF2RA  colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage)  
1441   CSF3R  colony stimulating factor 3 receptor (granulocyte)  
1436   CSF1R  colony stimulating factor 1 receptor (EC:2.7.10.1)  
3569   IL6  interleukin 6 (interferon, beta 2)  
1029   CDKN2A  cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)  
1871   E2F3  E2F transcription factor 3  
1869   E2F1  E2F transcription factor 1  
1870   E2F2  E2F transcription factor 2  
4149   MAX  MYC associated factor X  
8554   PIAS1  protein inhibitor of activated STAT, 1  
51588   PIAS4  protein inhibitor of activated STAT, 4  
10401   PIAS3  protein inhibitor of activated STAT, 3  
9063   PIAS2  protein inhibitor of activated STAT, 2  
1030   CDKN2B  cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)  
1021   CDK6  cyclin-dependent kinase 6 (EC:2.7.11.22)  
1163   CKS1B  CDC28 protein kinase regulatory subunit 1B  
6502   SKP2  S-phase kinase-associated protein 2, E3 ubiquitin protein ligase  
1017   CDK2  cyclin-dependent kinase 2 (EC:2.7.11.22)  
9134   CCNE2  cyclin E2  
898   CCNE1  cyclin E1  
5925   RB1  retinoblastoma 1  
4286   MITF  microphthalmia-associated transcription factor  
7040   TGFB1  transforming growth factor, beta 1  
7042   TGFB2  transforming growth factor, beta 2  
7043   TGFB3  transforming growth factor, beta 3  
7046   TGFBR1  transforming growth factor, beta receptor 1 (EC:2.7.11.30)  
7048   TGFBR2  transforming growth factor, beta receptor II (70/80kDa) (EC:2.7.11.30)  
4087   SMAD2  SMAD family member 2  
4088   SMAD3  SMAD family member 3  
4089   SMAD4  SMAD family member 4  
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2122   MECOM  MDS1 and EVI1 complex locus  
1488   CTBP2  C-terminal binding protein 2  
1487   CTBP1  C-terminal binding protein 1  
3066   HDAC2  histone deacetylase 2 (EC:3.5.1.98)  
3065   HDAC1  histone deacetylase 1 (EC:3.5.1.98)  
4292   MLH1  mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)  
4436   MSH2  mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)  
4437   MSH3  mutS homolog 3 (E. coli)  
2956   MSH6  mutS homolog 6 (E. coli)  
581   BAX  BCL2-associated X protein  
675   BRCA2  breast cancer 2, early onset  
5888   RAD51  RAD51 homolog (S. cerevisiae)  
356   FASLG  Fas ligand (TNF superfamily, member 6)  
355   FAS  Fas (TNF receptor superfamily, member 6)  
8772   FADD  Fas (TNFRSF6)-associated via death domain  
841   CASP8  caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61)  
637   BID  BH3 interacting domain death agonist  
54205   CYCS  cytochrome c, somatic  
7428   VHL  von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase  
6921   TCEB1  transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin 
C)  
6923   TCEB2  transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin 
B)  
9978   RBX1  ring-box 1, E3 ubiquitin protein ligase  
8453   CUL2  cullin 2  
112399   EGLN3  egl nine homolog 3 (C. elegans) (EC:1.14.11.29)  
112398   EGLN2  egl nine homolog 2 (C. elegans) (EC:1.14.11.29)  
54583   EGLN1  egl nine homolog 1 (C. elegans) (EC:1.14.11.29)  
2271   FH  fumarate hydratase (EC:4.2.1.2)  
3091   HIF1A  hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor)  
2034   EPAS1  endothelial PAS domain protein 1  
405   ARNT  aryl hydrocarbon receptor nuclear translocator  
9915   ARNT2  aryl-hydrocarbon receptor nuclear translocator 2  
1387   CREBBP  CREB binding protein (EC:2.3.1.48)  
2033   EP300  E1A binding protein p300 (EC:2.3.1.48)  
6513   SLC2A1  solute carrier family 2 (facilitated glucose transporter), member 1  
6469   SHH  sonic hedgehog  
5727   PTCH1  patched 1  
6608   SMO  smoothened, frizzled family receptor  
27148   STK36  serine/threonine kinase 36 (EC:2.7.11.1)  
51684   SUFU  suppressor of fused homolog (Drosophila)  
2737   GLI3  GLI family zinc finger 3  
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2736   GLI2  GLI family zinc finger 2  
2735   GLI1  GLI family zinc finger 1  
650   BMP2  bone morphogenetic protein 2  
652   BMP4  bone morphogenetic protein 4  
64399   HHIP  hedgehog interacting protein  
8643   PTCH2  patched 2  
367   AR  androgen receptor  
3320   HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A member 1  
3326   HSP90AB1  heat shock protein 90kDa alpha (cytosolic), class B member 1  
7184   HSP90B1  heat shock protein 90kDa beta (Grp94), member 1  
354   KLK3  kallikrein-related peptidase 3 (EC:3.4.21.77)  
112401   BIRC8  baculoviral IAP repeat containing 8  
2113   ETS1  v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)  
2950   GSTP1  glutathione S-transferase pi 1 (EC:2.5.1.18)  
5337   PLD1  phospholipase D1, phosphatidylcholine-specific (EC:3.1.4.4)  
79444   BIRC7  baculoviral IAP repeat containing 7  
8900   CCNA1  cyclin A1  
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Table S1.3. SBCGs (391) compiled for metastasis of primary breast and prostate cancer to 
bone. 
SBCGs compiled for metastasis of primary breast cancer to bone   
Gene Symbol Reference 
LRRC15, MMP13, MMP2, BCAM, COL10A1, AEBP1, IGFBP4, 
ESR1, AEBP1, ASPN, ATP6V0C, BCAM, COMP, CRIP1, DPT, 
IGFBP4, LRRC15, LRP1, MAB21L2, MMP13, MMP2, PDLIM7, 
PTOV1, PCDHGC3, RFNG, STK32B, TBC1D10B, TCIRG1, 
ZNF444  
[1] 
COX2, PGE2, TNFSF11, TNFRSF11A, FGF7, PTX3, NID2, 
RAP1GDS1, NPNT, COL6A3, IFIT3, IGRC, FMOD, IGIT1B, 
EGR1, PTGS2, CXCL10, VCAM1, FGF7, PTN, CD1D, LAMB1, 
CCL5, SFRP2, CXCL1 
[2] 
RASSF1A, MGMT, RAR-β2, APC [3] 
IBSP, SPP1, FGF13, COX7B2, SPARC, PRG1, GJA1, SOCS2, 
EDN1, IL11, CYR61, IGFBP4, IL8, PLAU, FST, MADH3, PTGS2, 
EXTL2, CTGF, CBFB, CDH11, S100A4, TIMP3, NOG, TGFA, 
THBS1, IGFBP3, PLAT, TIMP2, FN1, CCNB1, LRPAP1, MMP1, 
COL5A1, COL8A1, CALB2, CYR61, CTGF, WISP, BMP2, IL11, 
FST, CXCR4, ADAMTS1, MMP1, CX43, DUSP1, NOG, COX2, 
CBFB, GJA1, THBS1 
[4] 
SERPINB5 [5] 
ABCB1, ESR1, RUNDC3B, RAP2A [6] 
CSFIR [7] 
CAV1 [8] 
TGFB1, ATF3, MMP13, CCNA1 [9] 
COL1A1, VIM, S100A4, ACTA2, PDGFRB, NG2, CXCL1, CXCL5, 
PTGS2 
[10]  
HISTIH2AC, POMZP3, PON2, TMC5, SCNN1A, C10orf116, 
NAP1L3, GPRD5C, CTGF, FHL1, DUSP1, DLC1, SOCS2, IL11, 
ADAMTS1, CYP1B1, SAA2, SAA1, PPL, IL11, SPANXB1, FST, 
SERPINA1, HLA-DRA, HLA-DPA1, ABCC3, CSGALNACT1, 
FKBP11, CXCR4, PRG1, SES7-1, SOX4, KHDRBS3, FGF5, 
C14orf1139, PTX7, MCAM, TGFBI, S100A2, MMP1, FGF5, 
RGC32 
[11]  
TFF1, TFF3, AGR2, NAT1, CRIP1, TNRC9, SCUBE2, TNRC9, 
CYP2B6, RND1, DLALT1, KIF5C, PLA2GHB, UNG2, HMGCS2, 
SLC1A1, CEACAM6, TSPAN-1, REPS2, HPX, PDE4DIP, 
TOM1L1, SCGB2A2, ANXA9, BCAS1, TIMP4, CYP2B6, 
C9orf116, MSMB, FGFR3, FGFBP1, BAG1, FOXO3A, KRT16, 
MALL, KCNG1, IGLC2, KLK8, KRT6B, SNAI1, TMSNB, NRTN, 
EPHB3, ENO1, SOD2, IGHG1, KLK5, SOS, RARRES1, TTYH1, 
CD24, MGC27165, SERPINB5, UCHL1, ROPN1, LOC56901, 
ITGA6, TUBB, UBE4B, IGHM, COL2A1, IMPA2, DRE1, KLK7, 
TAZ, USP34, C6orf4, ALAD, ARHGDIA, ARS2, CLCA2, ELMO2, 
LRRC31, HTATSF1, HTR2B, MLPH, SLC2A8, TFPI2, BRCA1, 
BRCA2 
[12] 
DIP2B, MCM6, PLEK2 , FOXI1 , SYT13 , PRDM6 , LONP2, 
ZNF185, ENTPD4, PPP2R2C, LANCL2, SFTPD, TSGA10, 
B3GALT2, SEZ6L, KCND2, VSTM2, FANCL, FDPS , VRK2 
[13] 
HIF1A, VEGF, DUSP1, CXCR4 [14] 
IL1B, COL1A1, COL1A2, CTGF, IL10, IL8, SPP1, VCAM1, PGE2, 
EDN1, BMP6, IL6, PDGFRA, PTHLH, TGFB, LAMC2, IGFBP3, 
PLAU, TNF, TNFSF11,  TNFRSF11A, TNFRSF11B, CXCR4, 
[15] 
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CXCL12 
CXCR4, CXCL12, HER2 [16] 
PASAT1, PHGDH, PSPH, LTBP1, ATF3, CCNA1, MMP13 [17] 
ADAM9, ADAMTS1,  AREG, EGF, EGFR, ERBB2, HBEGF, 
MMP1, PTHLH, TNFRSF11A, TNFRSF11B 
[18] 
CTNNB1, DKK1, PLAU, PLAUR, SERPINB2, SERPINE1, WNT3A [19] 
BMP4, FGF1, FGF17, FGF4, FGF6, FGF8, IGF1, IL11, IL1B, IL6, 
IL8  
[20] 
CTTN, CXCL12, CXCR4, IL11, IL6,  [21] 
ADAMTS1, EGF, EGFR,  MMP1, TNFRSF11A, TNFRSF11B  [22] 
HIF1A [23] 
 
AKT1, AKT3, BMP2, CLEC11A, CXCL12, CXCR4, JAG1, NOV, 
PDGFA, PGF, PRG2, SPP1, SRC, TGFB1, TGFB3, TNFSF10, 
VEGFC 
[24] 
CTGF, NOV, WISP2, WISP3 [25] 
CSF1, IL8, PTHLH, TNFRSF11A,  TNFRSF11B [26] 
SBCGs compiled for metastasis of primary prostate cancer to bone   
APX1, ANTXR1, CDC23, CDC37, CETN3, CENPE, CCNC, 
CCNG1, CDK4, CDKN2C, CDKN3, CDKL1, DDB1, E2F1, FEN1, 
GTPBP4, KAT7, MCM7, MAD2L1,MSH6, NBN, PCNA, EIF2AK2, 
RAN, RPA2, RPA3, RRM2, SSBP1, SKP1, ADD1, DST, CDH1, 
CTNNAL1, CYB5R3,  DSC1, DSG2, ADAM9, FER, TNC, ITGB1, 
MFGE8, MCAM, ACVRL1, BGN, BST1, IBSP, CDH11, COL1A2, 
COL6A1, COL6A2, COL7A1, COL11A1, COL16A1, CSF1, DCN, 
FSTL1, INHA, MGP, SHH, VCAN, COL17A1, ITGB4, PLEC, 
DSC2, DSP, PKP1, PKP2, PKP3, PKP4, ASRGL1, BMP2, VDR, 
RUNX2, BGLAP, SPARC, SPP1, TNFRSF11B, TNFSF11, DRG1, 
PTHRP, EDN1, TNFRSF11A, TP53, HPN, TFF3, BGLAP, 
ERBB3, PSMD9, CDKN1A, MYCN, AR, HIF1A, MAGEA1, VEGF, 
KLK3, GDF15, BMP6, ERBB2, LTBP1, MMP9, MMP1, MMP3, 
PLAU, HRAS, NRAS, KRT1, PTRF, MDM2, RB1 
[27] 
HPN [28] 
TFF3 [29] 
BGLAP [30] 
ERBB3 [31] 
PSMD9, CDKN1A [27] 
ERBB2, EGFR [32]  
PALB, TGFB1, EGFR, BMP [33] 
BIN1, MYC, ABL1 [34] 
MAGEA1 [35] 
MMP1, MMP2, MMP13, DRG1, PTEN, NME1, CD82, KISS1, 
BRMS1, MAP2K4, TP53 
[36] 
IGFBP3, PTH1R, TNFSF11, MMP, MDM2, RB1, TNFRSF11A [37] 
RB1 [38] 
CDH11 [39] 
LYN, SRC [40]  
ADAMTS1, AREG, EGF, EGFR, HBEGF, PTHLH, TGFΑ, TNF, 
TNFRSF11A, TNFRSF11B, VEGFA 
[18] 
VEGFA, NR1I2 [41] 
AKT1, PTHLH, TNFRSF11A, TNFRSF11B [42] 
BMP4, CSF1, DKK1, IL8, NOG, PTHLH, SFRP1, SFRP2,  
TGFB1, TNFRSF11A, TNFRSF11B 
[43] 
RAP1GAP, TERF2IP, VTNR [44] 
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CXCL12, CXCR4, MAPK1, MAPK3,  [45] 
FGF1, FGF17, FGF4, FGF6, FGF8, FGFR3, [46] 
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Table S1.4. Significantly enriched GO terms, characteristic to metastasis to bone, identified 
from enrichment analysis of SBCGs.  
GO ID GO terms Reference 
Bone related processes 
GO:0001958 endochondral ossification [1] 
GO:0036075 replacement ossification [1] 
GO:0030282 bone mineralization [1] 
GO:0030199 collagen fibril organization [2] 
GO:0032963 collagen metabolic process [2] 
GO:0033280 response to vitamin D [3] 
GO:0046850 regulation of bone remodeling [4] 
GO:0001649 osteoblast differentiation [1,4] 
GO:0001503 ossification [1] 
GO:0051216 cartilage development [1] 
Metastasis related processes 
GO:0002690 positive regulation of leukocyte chemotaxis [5] 
GO:0002688 regulation of leukocyte chemotaxis [5] 
GO:0002687 positive regulation of leukocyte migration [5] 
GO:0050920 regulation of chemotaxis [5] 
GO:0007162 negative regulation of cell adhesion [6]  
GO:0002685 regulation of leukocyte migration [7] 
GO:0050900 leukocyte migration [7] 
GO:0016337 cell-cell adhesion [6,8] 
GO:0001525 angiogenesis [9,10] 
GO:0050679 positive regulation of epithelial cell proliferation [3] 
GO:0045785 positive regulation of cell adhesion [6] 
GO:0043236 laminin binding [11] 
GO:0001968 fibronectin binding [12,13] 
GO:0005104 fibroblast growth factor receptor binding [14] 
GO:0048407 platelet-derived growth factor binding [15,16] 
GO:0005518 collagen binding [2,17] 
GO:0005178 integrin binding [12,18] 
GO:0005539 glycosaminoglycan binding [19] 
GO:0005125 cytokine activity [20,21] 
GO:0030246 carbohydrate binding [22] 
GO:0035413 positive regulation of catenin import into nucleus [23] 
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Table S1.5. Relevance of SBC Targets. 
SBC Specific 
Targets 
Reference 
TNXB [1]  
SPP1 [2]  
CTGF [3–5] 
BMP1 [6]  
BMPR1A [6]  
CD44 [7]  
VWF [8]  
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